Effect of immunomodulators on specific tumor immunity induced by liposome‐encapsulated tumor‐associated antigens
- 1 March 1994
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 56 (5) , 721-726
- https://doi.org/10.1002/ijc.2910560518
Abstract
Reconstituted membranes consist of liposomal structures formed by removal of detergent from solubilized membrane constituents. The membrane-like configuration of reconstituted membranes makes them attractive as vehicles for presentation of tumor-associated antigens and induction of immune responses. In this study the potential of immunomodulators was assessed to enhance the specific immune response induced by immunization with reconstituted membranes prepared from SL2 lymphosarcoma cells. Reconstituted membranes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) provided better protection against a challenge with SL2 cells than did reconstituted membranes containing alternative immunomodulators. Local administration of IL-2 at the immunization sites further augmented the protection induced by reconstituted membranes with MTP-PE, but was ineffective when administered with plain reconstituted membranes. Immunity elicited by the triple modality of reconstituted SL2 membranes with MTP-PE and IL-2 was specific for SL2 cells. Systemic immunity was obtained against a challenge with a 100-fold higher number of SL2 cells than was reached after immunization with reconstituted membranes alone (105 vs. 10 SL2 cells). Macrophages isolated from the peritoneal cavity of immunized mice 5 to 7 days after tumor challenge expressed high In vitro cytotoxicity. However, in contrast to the observed specificity of the systemic immunity, macrophages killed both SL2 cells and non-related P815 cells. Neither major cytotoxic lymphocyte activity nor substantial cytotoxic antibody tilers were detectable. These results clearly indicate that the approach using reconstituted membranes combined with particular immunomodulators warrants further exploration for the development of safe, well-characterized cancer vaccines.Keywords
This publication has 18 references indexed in Scilit:
- A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipidsPublished by Elsevier ,2004
- Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in miceCancer Immunology, Immunotherapy, 1993
- Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cellsCancer Immunology, Immunotherapy, 1992
- MTP-PE in liposomes as a biological response modifier in the treatment of cancer: Current statusBiotherapy, 1992
- Liposome‐mediated delivery stimulates a class I‐restricted cytotoxic T cell response to soluble antigenEuropean Journal of Immunology, 1992
- pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble proteinJournal of Immunological Methods, 1991
- Induction of in vitro and in vivo anti‐tumor responses by sensitization of mice with liposomes containing a crude butanol extract of leukemia cells and transferred inter‐membranously with cell‐surface proteinsInternational Journal of Cancer, 1991
- Immunological adjuvants: a role for liposomesImmunology Today, 1990
- Cancer Vaccines Show Promise at LastScience, 1989
- Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejectionCancer Immunology, Immunotherapy, 1989